Loading...
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the...
Na minha lista:
| Udgivet i: | J Transl Med |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5941640/ https://ncbi.nlm.nih.gov/pubmed/29739427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1499-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|